Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3048% below fair value
$1.71+0.09 (+5.56%)
Close on Nov 13, 2026Market cap $14.10MP/E –Yield –
Lipocine EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Lipocine's EPS for the twelve months ending Sep 30, 2026 was -$1.29. For fiscal 2025 it was -$1.69. The highest annual figure on record is $14.45 in fiscal 2012.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.69 | – |
| FY2023 | Dec 31, 2023 | -$3.14 | – |
| FY2022 | Dec 31, 2022 | -$2.15 | – |
| FY2021 | Dec 31, 2021 | -$0.17 | – |
| FY2020 | Dec 31, 2020 | -$6.46 | – |
| FY2019 | Dec 31, 2019 | -$8.50 | – |
| FY2018 | Dec 31, 2018 | -$9.35 | – |
| FY2017 | Dec 31, 2017 | -$17.85 | – |
| FY2016 | Dec 31, 2016 | -$17.68 | – |
| FY2015 | Dec 31, 2015 | -$18.87 | – |
| FY2014 | Dec 31, 2014 | -$27.20 | – |
| FY2013 | Dec 31, 2013 | -$24.48 | -269.4% |
| FY2012 | Dec 31, 2012 | $14.45 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.08 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.32 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.54 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.35 | -212.9% |
| Q3 FY2025 | Sep 30, 2025 | -$0.59 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.41 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.35 | -153.0% |
| Q4 FY2024 | Dec 31, 2024 | $0.31 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.44 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.56 | – |
| Q1 FY2024 | Mar 31, 2024 | $0.66 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.43 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.27 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.68 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.76 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.43 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.52 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.61 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.68 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.68 | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.36 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.68 | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.15 | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.19 | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.21 | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.38 | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.83 | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.04 | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.38 | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.38 | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.55 | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.04 | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.55 | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.21 | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.25 | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.74 | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.27 | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.42 | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.72 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?